332 related articles for article (PubMed ID: 24366930)
1. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis.
Stelljes M; Krug U; Beelen DW; Braess J; Sauerland MC; Heinecke A; Ligges S; Sauer T; Tschanter P; Thoennissen GB; Berning B; Kolb HJ; Reichle A; Holler E; Schwerdtfeger R; Arnold R; Scheid C; Müller-Tidow C; Woermann BJ; Hiddemann W; Berdel WE; Büchner T
J Clin Oncol; 2014 Feb; 32(4):288-96. PubMed ID: 24366930
[TBL] [Abstract][Full Text] [Related]
2. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M
Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939
[TBL] [Abstract][Full Text] [Related]
3. Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission.
Usuki K; Kurosawa S; Uchida N; Yakushiji K; Waki F; Matsuishi E; Kagawa K; Furukawa T; Maeda Y; Shimoyama M; Ago H; Yamano Y; Yano S; Fujishima N; Takamatsu Y; Eto T; Hidaka M; Matsuoka H; Fukuda T
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):444-51. PubMed ID: 22999942
[TBL] [Abstract][Full Text] [Related]
4. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.
Kalaycio M; Advani A; Pohlman B; Sekeres M; Tripp B; Rybicki L; Sobecks R
Am J Hematol; 2008 Nov; 83(11):831-4. PubMed ID: 18756545
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories.
Cornelissen JJ; Breems D; van Putten WL; Gratwohl AA; Passweg JR; Pabst T; Maertens J; Beverloo HB; van Marwijk Kooy M; Wijermans PW; Biemond BJ; Vellenga E; Verdonck LF; Ossenkoppele GJ; Löwenberg B
J Clin Oncol; 2012 Jun; 30(17):2140-6. PubMed ID: 22564995
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.
Juliusson G; Karlsson K; Lazarevic VLj; Wahlin A; Brune M; Antunovic P; Derolf A; Hägglund H; Karbach H; Lehmann S; Möllgård L; Stockelberg D; Hallböök H; Höglund M;
Cancer; 2011 Sep; 117(18):4238-46. PubMed ID: 21387283
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A.
Schlenk RF; Döhner K; Mack S; Stoppel M; Király F; Götze K; Hartmann F; Horst HA; Koller E; Petzer A; Grimminger W; Kobbe G; Glasmacher A; Salwender H; Kirchen H; Haase D; Kremers S; Matzdorff A; Benner A; Döhner H
J Clin Oncol; 2010 Oct; 28(30):4642-8. PubMed ID: 20805454
[TBL] [Abstract][Full Text] [Related]
8. HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up.
Guo M; Hu KX; Liu GX; Yu CL; Qiao JH; Sun QY; Qiao JX; Dong Z; Sun WJ; Sun XD; Zuo HL; Man QH; Liu ZQ; Liu TQ; Zhao HX; Huang YJ; Wei L; Liu B; Wang J; Shen XL; Ai HS
J Clin Oncol; 2012 Nov; 30(33):4084-90. PubMed ID: 23045576
[TBL] [Abstract][Full Text] [Related]
9. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
Jackson K; Kennedy G; Mollee P; Marlton P; Morris K
Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
Kobos R; Steinherz PG; Kernan NA; Prockop SE; Scaradavou A; Small TN; Shukla N; Khalaf R; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
[TBL] [Abstract][Full Text] [Related]
11. Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemia.
Hsieh YY; Hong YC; Hsiao LT; Yu YB; Liu JH; Gau JP; Lin HN; Hsu YN; Chiou TJ; Chen PM; Tzeng CH; Liu CY
Eur J Haematol; 2011 Mar; 86(3):237-45. PubMed ID: 21155895
[TBL] [Abstract][Full Text] [Related]
12. Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission.
Hemmati PG; Terwey TH; Na IK; le Coutre P; Jehn CF; Vuong LG; Dörken B; Arnold R
Eur J Haematol; 2015 May; 94(5):431-8. PubMed ID: 25220715
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission.
Hemmati PG; Schulze-Luckow A; Terwey TH; le Coutre P; Vuong LG; Dörken B; Arnold R
Eur J Haematol; 2014 Feb; 92(2):102-10. PubMed ID: 24138573
[TBL] [Abstract][Full Text] [Related]
15. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.
Chen Y; Cortes J; Estrov Z; Faderl S; Qiao W; Abruzzo L; Garcia-Manero G; Pierce S; Huang X; Kebriaei P; Kadia T; De Lima M; Kantarjian H; Ravandi F
J Clin Oncol; 2011 Jun; 29(18):2507-13. PubMed ID: 21555694
[TBL] [Abstract][Full Text] [Related]
16. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
17. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.
Schlenk RF; Benner A; Hartmann F; del Valle F; Weber C; Pralle H; Fischer JT; Gunzer U; Pezzutto A; Weber W; Grimminger W; Preiss J; Hensel M; Fröhling S; Döhner K; Haas R; Döhner H;
Leukemia; 2003 Aug; 17(8):1521-8. PubMed ID: 12886238
[TBL] [Abstract][Full Text] [Related]
18. Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Østgård LSG; Lund JL; Nørgaard JM; Nørgaard M; Medeiros BC; Nielsen B; Nielsen OJ; Overgaard UM; Kallenbach M; Marcher CW; Riis AH; Sengeløv H
Biol Blood Marrow Transplant; 2018 Feb; 24(2):314-323. PubMed ID: 29051022
[TBL] [Abstract][Full Text] [Related]
19. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
Schmid C; Schleuning M; Hentrich M; Markl GE; Gerbitz A; Tischer J; Ledderose G; Oruzio D; Hiddemann W; Kolb HJ
Bone Marrow Transplant; 2008 Apr; 41(8):721-7. PubMed ID: 18176613
[TBL] [Abstract][Full Text] [Related]
20. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
Tsimberidou AM; Stavroyianni N; Viniou N; Papaioannou M; Tiniakou M; Marinakis T; Skandali A; Sakellari I; Yataganas X;
Cancer; 2003 Apr; 97(7):1721-31. PubMed ID: 12655529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
